CHMP-话题@MedSci

#CHMP#

108篇内容 | 1680人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1302713, encodeId=94281302e137b, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, objectTitle=欧盟CHMP为两款CAR-T疗法Carvykti和Kymriah大开绿灯, objectType=article, longId=301794, objectId=e0bb301e9432, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0bb301e9432, replyNumber=0, likeNumber=54, createdTime=2022-03-29, rootId=0, userName=医生2394, userId=b505306, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0bb301e9432, moduleTitle=欧盟CHMP为两款CAR-T疗法Carvykti和Kymriah大开绿灯, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0bb301e9432)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302712, encodeId=25571302e12c0, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, objectTitle=CHMP对Valneva的COVID-19疫苗进行初步评估, objectType=article, longId=300370, objectId=3f0d3003e02a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f0d3003e02a, replyNumber=0, likeNumber=51, createdTime=2022-03-11, rootId=0, userName=医生2394, userId=b505306, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f0d3003e02a, moduleTitle=CHMP对Valneva的COVID-19疫苗进行初步评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f0d3003e02a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302711, encodeId=39ef1302e1199, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, objectTitle=失眠患者的福音，CHMP推荐双效食欲素受体拮抗剂Quviviq, objectType=article, longId=300369, objectId=43ec300369f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43ec300369f4, replyNumber=0, likeNumber=54, createdTime=2022-03-11, rootId=0, userName=医生2394, userId=b505306, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43ec300369f4, moduleTitle=失眠患者的福音，CHMP推荐双效食欲素受体拮抗剂Quviviq, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43ec300369f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302710, encodeId=83931302e10e6, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, objectTitle=CHMP支持Opdivo治疗食管、尿路上皮癌, objectType=article, longId=299738, objectId=b3b3299e38c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3b3299e38c5, replyNumber=0, likeNumber=37, createdTime=2022-03-01, rootId=0, userName=医生2394, userId=b505306, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3b3299e38c5, moduleTitle=CHMP支持Opdivo治疗食管、尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3b3299e38c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302709, encodeId=bd1f1302e0932, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, objectTitle=晚期全身性肥大细胞增多症患者的福音，Ayvakyt已获得CHMP的积极意见, objectType=article, longId=295076, objectId=3c842950e643, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c842950e643, replyNumber=0, likeNumber=60, createdTime=2022-02-04, rootId=0, userName=医生2394, userId=b505306, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c842950e643, moduleTitle=晚期全身性肥大细胞增多症患者的福音，Ayvakyt已获得CHMP的积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c842950e643)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302708, encodeId=7cc91302e08fa, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, objectTitle=幼儿哮喘患者的福音，CHMP批准Dupixent用于患有哮喘的幼儿患者, objectType=article, longId=295015, objectId=7fac295015e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fac295015e8, replyNumber=0, likeNumber=48, createdTime=2022-02-03, rootId=0, userName=医生2394, userId=b505306, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fac295015e8, moduleTitle=幼儿哮喘患者的福音，CHMP批准Dupixent用于患有哮喘的幼儿患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fac295015e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302707, encodeId=fdbd1302e07b6, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, objectTitle=CHMP推荐Saphnelo治疗系统性红斑狼疮, objectType=article, longId=292769, objectId=1811292e69d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1811292e69d6, replyNumber=0, likeNumber=57, createdTime=2021-12-27, rootId=0, userName=医生2394, userId=b505306, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1811292e69d6, moduleTitle=CHMP推荐Saphnelo治疗系统性红斑狼疮, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1811292e69d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302706, encodeId=c4881302e063e, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, objectTitle=Finerenone用于与2型糖尿病相关的慢性肾病，CHMP持正面意见, objectType=article, longId=292568, objectId=00f32925683d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00f32925683d, replyNumber=0, likeNumber=36, createdTime=2021-12-24, rootId=0, userName=医生2394, userId=b505306, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00f32925683d, moduleTitle=Finerenone用于与2型糖尿病相关的慢性肾病，CHMP持正面意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00f32925683d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302705, encodeId=8d9a1302e052f, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, objectTitle=CHMP对 Kineret (anakinra) 治疗COVID-19持积极意见, objectType=article, longId=292250, objectId=43db292250ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43db292250ee, replyNumber=0, likeNumber=48, createdTime=2021-12-21, rootId=0, userName=医生2394, userId=b505306, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43db292250ee, moduleTitle=CHMP对 Kineret (anakinra) 治疗COVID-19持积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43db292250ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302704, encodeId=889e1302e042b, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, objectTitle=CHMP建议批准罗氏的COVID-19疗法, objectType=article, longId=221771, objectId=1e47221e71bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e47221e71bb, replyNumber=0, likeNumber=50, createdTime=2021-12-11, rootId=0, userName=医生2394, userId=b505306, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e47221e71bb, moduleTitle=CHMP建议批准罗氏的COVID-19疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e47221e71bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302703, encodeId=4c2d1302e0382, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, objectTitle=Celltrion收到CHMP对首批推荐用于治疗新冠肺炎的单克隆抗体之一瑞丹维单抗(CT-P59)的肯定意见, objectType=article, longId=220399, objectId=c27f220399db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c27f220399db, replyNumber=0, likeNumber=47, createdTime=2021-11-17, rootId=0, userName=医生2394, userId=b505306, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c27f220399db, moduleTitle=Celltrion收到CHMP对首批推荐用于治疗新冠肺炎的单克隆抗体之一瑞丹维单抗(CT-P59)的肯定意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c27f220399db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302702, encodeId=90d21302e025b, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, objectTitle=Zeposia (ozanimod) 治疗中重度活动性溃疡性结肠炎成人患者，CHMP持积极意见, objectType=article, longId=218759, objectId=d752218e59cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d752218e59cc, replyNumber=0, likeNumber=57, createdTime=2021-10-19, rootId=0, userName=医生2394, userId=b505306, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d752218e59cc, moduleTitle=Zeposia (ozanimod) 治疗中重度活动性溃疡性结肠炎成人患者，CHMP持积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d752218e59cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302701, encodeId=a5141302e01dc, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, objectTitle=欧盟人用药品委员会 (CHMP) 对sacituzumab govitecan单药治疗三阴性乳腺癌 (TNBC) 持积极意见, objectType=article, longId=218739, objectId=cba7218e390b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cba7218e390b, replyNumber=0, likeNumber=53, createdTime=2021-10-18, rootId=0, userName=医生2394, userId=b505306, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cba7218e390b, moduleTitle=欧盟人用药品委员会 (CHMP) 对sacituzumab govitecan单药治疗三阴性乳腺癌 (TNBC) 持积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cba7218e390b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302700, encodeId=f4761302e0006, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, objectTitle=Aspaveli (pegcetacoplan) 治疗阵发性夜间血红蛋白尿症 (PNH)，已获得欧盟CHMP积极意见, objectType=article, longId=218729, objectId=4cd6218e291b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cd6218e291b, replyNumber=0, likeNumber=60, createdTime=2021-10-18, rootId=0, userName=医生2394, userId=b505306, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cd6218e291b, moduleTitle=Aspaveli (pegcetacoplan) 治疗阵发性夜间血红蛋白尿症 (PNH)，已获得欧盟CHMP积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cd6218e291b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302699, encodeId=79ed13026990a, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, objectTitle=Abrocitinib获得CHMP的积极意见，用于治疗成人中重度特应性皮炎, objectType=article, longId=218693, objectId=91f621869309, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91f621869309, replyNumber=0, likeNumber=43, createdTime=2021-10-17, rootId=0, userName=医生2394, userId=b505306, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91f621869309, moduleTitle=Abrocitinib获得CHMP的积极意见，用于治疗成人中重度特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91f621869309)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302698, encodeId=402113026986b, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, objectTitle=Tecentriq一线治疗转移性非小细胞肺癌，CHMP持积极意见, objectType=article, longId=209090, objectId=e891209090ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e891209090ea, replyNumber=0, likeNumber=50, createdTime=2021-03-29, rootId=0, userName=医生2394, userId=b505306, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e891209090ea, moduleTitle=Tecentriq一线治疗转移性非小细胞肺癌，CHMP持积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e891209090ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302697, encodeId=09df130269e5f, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, objectTitle=CHMP建议批准Benlysta用于治疗活动性狼疮性肾炎, objectType=article, longId=209085, objectId=72692090857f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72692090857f, replyNumber=0, likeNumber=38, createdTime=2021-03-29, rootId=0, userName=医生2394, userId=b505306, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72692090857f, moduleTitle=CHMP建议批准Benlysta用于治疗活动性狼疮性肾炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72692090857f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302696, encodeId=24161302696b0, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, objectTitle=Opdivo（nivolumab）联合Cabometyx（cabozantinib）一线治疗晚期肾细胞癌，CHMP持积极意见, objectType=article, longId=207706, objectId=989b20e706d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=989b20e706d8, replyNumber=0, likeNumber=51, createdTime=2021-03-01, rootId=0, userName=医生2394, userId=b505306, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=989b20e706d8, moduleTitle=Opdivo（nivolumab）联合Cabometyx（cabozantinib）一线治疗晚期肾细胞癌，CHMP持积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=989b20e706d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302695, encodeId=5ede13026956a, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, objectTitle=CHMP建议批准Sarclisa（isatuximab）与卡非佐米和地塞米松联合治疗复发性多发性骨髓瘤, objectType=article, longId=207705, objectId=73c620e7058a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73c620e7058a, replyNumber=0, likeNumber=47, createdTime=2021-03-01, rootId=0, userName=医生2394, userId=b505306, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73c620e7058a, moduleTitle=CHMP建议批准Sarclisa（isatuximab）与卡非佐米和地塞米松联合治疗复发性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73c620e7058a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1302694, encodeId=ae2d1302694b7, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, objectTitle=Evrysdi治疗脊髓性肌萎缩症（SMA），CHMP持积极意见, objectType=article, longId=207698, objectId=b1e420e698d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1e420e698d6, replyNumber=0, likeNumber=47, createdTime=2021-03-01, rootId=0, userName=医生2394, userId=b505306, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1e420e698d6, moduleTitle=Evrysdi治疗脊髓性肌萎缩症（SMA），CHMP持积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1e420e698d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

2020-05-29

医生2394 (审核中...)

前往app查看评论内容

#CHMP#

欧盟CHMP为两款CAR-T疗法Carvykti和Kymriah大开绿灯

2022-03-29

医生2394 (审核中...)

前往app查看评论内容

#CHMP#

CHMP对Valneva的COVID-19疫苗进行初步评估

2022-03-11

医生2394 (审核中...)

前往app查看评论内容

#CHMP#

失眠患者的福音，CHMP推荐双效食欲素受体拮抗剂Quviviq

2022-03-11

医生2394 (审核中...)

前往app查看评论内容

#CHMP#

CHMP支持Opdivo治疗食管、尿路上皮癌

2022-03-01

医生2394 (审核中...)

前往app查看评论内容

#CHMP#

晚期全身性肥大细胞增多症患者的福音，Ayvakyt已获得CHMP的积极意见

2022-02-04

医生2394 (审核中...)

前往app查看评论内容

#CHMP#

幼儿哮喘患者的福音，CHMP批准Dupixent用于患有哮喘的幼儿患者

2022-02-03

医生2394 (审核中...)

前往app查看评论内容

#CHMP#

CHMP推荐Saphnelo治疗系统性红斑狼疮

2021-12-27

医生2394 (审核中...)

前往app查看评论内容

#CHMP#

Finerenone用于与2型糖尿病相关的慢性肾病，CHMP持正面意见

2021-12-24

医生2394 (审核中...)

前往app查看评论内容

#CHMP#

CHMP对 Kineret (anakinra) 治疗COVID-19持积极意见

2021-12-21

医生2394 (审核中...)

前往app查看评论内容

#CHMP#

CHMP建议批准罗氏的COVID-19疗法

2021-12-11

医生2394 (审核中...)

前往app查看评论内容

#CHMP#

Celltrion收到CHMP对首批推荐用于治疗新冠肺炎的单克隆抗体之一瑞丹维单抗(CT-P59)的肯定意见

2021-11-17

医生2394 (审核中...)

前往app查看评论内容

#CHMP#

Zeposia (ozanimod) 治疗中重度活动性溃疡性结肠炎成人患者，CHMP持积极意见

2021-10-19

医生2394 (审核中...)

前往app查看评论内容

#CHMP#

欧盟人用药品委员会 (CHMP) 对sacituzumab govitecan单药治疗三阴性乳腺癌 (TNBC) 持积极意见

2021-10-18

医生2394 (审核中...)

前往app查看评论内容

#CHMP#

Aspaveli (pegcetacoplan) 治疗阵发性夜间血红蛋白尿症 (PNH)，已获得欧盟CHMP积极意见

2021-10-18

医生2394 (审核中...)

前往app查看评论内容

#CHMP#

Abrocitinib获得CHMP的积极意见，用于治疗成人中重度特应性皮炎

2021-10-17

医生2394 (审核中...)

前往app查看评论内容

#CHMP#

Tecentriq一线治疗转移性非小细胞肺癌，CHMP持积极意见

2021-03-29

医生2394 (审核中...)

前往app查看评论内容

#CHMP#

CHMP建议批准Benlysta用于治疗活动性狼疮性肾炎

2021-03-29

医生2394 (审核中...)

前往app查看评论内容

#CHMP#

Opdivo（nivolumab）联合Cabometyx（cabozantinib）一线治疗晚期肾细胞癌，CHMP持积极意见

2021-03-01

医生2394 (审核中...)

前往app查看评论内容

#CHMP#

CHMP建议批准Sarclisa（isatuximab）与卡非佐米和地塞米松联合治疗复发性多发性骨髓瘤

2021-03-01

医生2394 (审核中...)

前往app查看评论内容

#CHMP#

Evrysdi治疗脊髓性肌萎缩症（SMA），CHMP持积极意见

2021-03-01

科室
- - 订阅+
  - 更多科室
工具
服务